<DOC>
	<DOCNO>NCT00014326</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Giving radiation therapy different way may kill tumor cell . It yet know regimen radiation therapy effective non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy involve area without total-body irradiation treat patient low-grade stage I stage II non-Hodgkin 's lymphoma previously treat .</brief_summary>
	<brief_title>Involved-Field Radiation Therapy Treating Patients With Previously Untreated Stage I Stage II Low-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine addition low-dose total body irradiation ( TBI ) involved-field radiotherapy improve disease-free survival patient previously untreated , stage I II low-grade non-Hodgkin 's lymphoma . - Determine response patient treat low-dose TBI . - Compare overall survival quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , stage ( I vs II ) , performance status ( 0-1 v 2 ) , lactate dehydrogenase elevation ( yes v ) , histological subtype ( small lymphocytic lymphoma v lymphoplasmacytoid lymphoma v follicular lymphoma ) , , stage I patient , presence measurable mass ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo involved-field radiotherapy daily five day week 2.5-4 week . - Arm II : Patients undergo low-dose total body irradiation ( TBI ) daily 5 day week week 1 4 . At 4 week completion TBI , patient undergo involved-field radiotherapy arm I . Quality life assess treatment , 4 week completion involved-field radiotherapy , every 6 month 5 year , annually thereafter . Patients follow every 3 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 344 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage I II , lowgrade , nonHodgkin 's lymphoma Follicular lymphoma grade I , II , III Small lymphocytic lymphoma Lymphoplasmacytoid lymphoma Nodal marginal zone lymphoma Previously untreated disease At least 1 measurable evaluable mass least 1.1 cm ( except patient stage I disease entire mass remove diagnostic purpose ) NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC great 2,000/mm ^3 Platelet count great 100,000/mm^3 Hepatic : Not specify Renal : Not specify Other : No prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix No psychological , familial , sociological , geographical condition would preclude study participation Not pregnant nursing Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
</DOC>